Beam Therapeutics Inc.

BMV:BEAM * Stock Report

Market Cap: Mex$50.3b

Beam Therapeutics Management

Management criteria checks 3/4

Beam Therapeutics' CEO is John Evans, appointed in Jan 2017, has a tenure of 9.58 years. total yearly compensation is $5.82M, comprised of 13% salary and 87% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth MX$477.98M. The average tenure of the management team and the board of directors is 6 years and 5.6 years respectively.

Key information

John Evans

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage12.98%
CEO tenure9.6yrs
CEO ownership0.9%
Management average tenure6yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Evans's remuneration changed compared to Beam Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$87m

Mar 31 2026n/an/a

-US$66m

Dec 31 2025US$6mUS$755k

-US$80m

Sep 30 2025n/an/a

-US$414m

Jun 30 2025n/an/a

-US$397m

Mar 31 2025n/an/a

-US$386m

Dec 31 2024US$6mUS$716k

-US$377m

Sep 30 2024n/an/a

-US$144m

Jun 30 2024n/an/a

-US$143m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$685k

-US$133m

Sep 30 2023n/an/a

-US$314m

Jun 30 2023n/an/a

-US$327m

Mar 31 2023n/an/a

-US$316m

Dec 31 2022US$9mUS$650k

-US$289m

Sep 30 2022n/an/a

-US$315m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$238m

Dec 31 2021US$14mUS$590k

-US$371m

Sep 30 2021n/an/a

-US$401m

Jun 30 2021n/an/a

-US$408m

Mar 31 2021n/an/a

-US$366m

Dec 31 2020US$907kUS$529k

-US$196m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$106m

Dec 31 2019US$2mUS$473k

-US$91m

Compensation vs Market: John's total compensation ($USD5.82M) is above average for companies of similar size in the MX market ($USD1.22M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Evans (48 yo)

9.6yrs
Tenure
US$5,818,526
Compensation

Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2017. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...

Leadership Team

NamePositionTenureCompensationOwnership
John Evans
CEO & Director9.6yrsUS$5.82m0.95%
MX$ 478.0m
Giuseppe Ciaramella
President6.6yrsUS$3.16m0.25%
MX$ 127.9m
Sravan Emany
Chief Financial Officer1.7yrsUS$1.30m0.014%
MX$ 6.9m
Christine Bellon
Chief Legal Officer & Corporate Secretary7.3yrsUS$1.97m0.11%
MX$ 55.2m
Amy Simon
Chief Medical Officer5.4yrsUS$2.80m0.0021%
MX$ 1.0m
Feng Zhang
Co-Founderno datano datano data
David Liu
Co-Founderno datano datano data
J. Joung
Co-Founderno datano datano data
Bethany Cavanagh
Senior VP of Financeno datano data0.013%
MX$ 6.8m
Manmohan Singh
Chief Technology Officerno datano datano data
Gopi Shanker
Chief Scientific Officer3.4yrsno datano data
Holly Manning
Vice President of Investor Relations & External Communicationsno datano datano data
6.0yrs
Average Tenure
57yo
Average Age

Experienced Management: BEAM *'s management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Evans
CEO & Director9.6yrsUS$5.82m0.95%
MX$ 478.0m
John Michael Maraganore
Independent Director4.8yrsUS$465.65k0%
MX$ 0
Mark Fishman
Independent Lead Director8.3yrsUS$495.23k0.017%
MX$ 8.6m
Graham Cooper
Independent Director6.8yrsUS$468.15k0%
MX$ 0
Kathleen Walsh
Independent Director5.6yrsUS$465.65k0%
MX$ 0
Chirfi Guindo
Independent Director1.7yrsUS$455.65k0%
MX$ 0
Christi Shaw
Independent Director2.7yrsUS$463.15k0%
MX$ 0
5.6yrs
Average Tenure
60yo
Average Age

Experienced Board: BEAM *'s board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/22 13:55
End of Day Share Price 2026/08/17 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Beam Therapeutics Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PickeringBernstein
Alec StranahanBofA Global Research
Whitney IjemCanaccord Genuity